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Abstract
The amyloidoses are a heterogenous group of clinical disorders that share the 
common finding of the abnormal deposition of insoluble proteins into various 
organs, with the result that these proteinaceous deposits disrupt cellular func-
tion and impair the integrity of the organs involved. Most typically, the abnormal 
protein deposition is the consequence of abnormal three dimensional folding of the 
culprit protein. The abnormal folding of the protein, in turn, may be due to a germ 
line mutation, may be due to an acquired mutation, or may be due to a polymor-
phism or characteristic of a normal protein that leads to abnormal folding, precipi-
tation, and deposition of the protein, particularly when that protein is expressed at 
unusually high levels for a prolonged period of time. The clinical manifestations of 
an amyloid disorder are the consequences of the array of organs involved, the extent 
of amyloid deposition, and co-morbid conditions present in the individual patient. 
The array of organs involved, and the extent of organ involvement, in turn, depend 
in large part on the specific protein that is responsible for the amyloid deposition, 
and the process driving that protein’s production. In this chapter, a chronological 
overview is intended to summarize the critical insights into the patho-biology of 
amyloid accumulation of various types. These insights have allowed an improved 
understanding over time of the of the major subgroups and disease entities of the 
amyloidoses, leading to some degree of improvement in diagnosis and treatment 
outcomes. Unfortunately, as of this writing, treatment outcomes still remain poor 
for a large fraction of patients, and there is need for improvement in all aspects of 
the evaluation and management of these diseases.
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1. Introduction
The amyloidoses are a heterogenous group of clinical disorders that share the 
common finding of the abnormal deposition of insoluble proteins into various 
organs, with the re sult that these proteinaceous deposits disrupt cellular func-
tion and impair the integrity of the organs involved. Most typically, the abnormal 
protein deposition is the consequence of abnormal three dimensional folding of the 
culprit protein. The abnormal folding of the protein, in turn, may be due to a germ 
line mutation - in which case the disease is a hereditary amyloidosis; the abnormal 
folding may be due to an acquired mutation, for example a mutation resulting 
in a B cell lymphoproliferative disorder as is seen in AL amyoidosis, also termed 
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primary amyloidosis - in which an excess of an abnormal immunoglobulin light 
chain misfolds and results in amyloid deposition; or may be due to a polymorphism 
in the culprit protein that leads to abnormal folding, then precipitation, and then 
deposition of the protein, particularly when that protein is expressed at unusu-
ally high levels for a prolonged time period, as in the subtype of amyloid diseases 
termed AA amyloidosis, or as in renal dialysis associated amyloidosis. The clinical 
manifestations of an amyloid disorder are the consequences of the array of organs 
involved, the extent of amyloid deposition, and co-morbid conditions present in the 
individual patient. The array of organs involved, and the extent of organ involve-
ment, in turn, depend in large part on the specific protein that is responsible for the 
amyloid deposition, and the process driving that protein’s production.
In this chapter, a chronological overview is intended to summarize the critical 
insights, over time, into the patho-biology of amyloid accumulation of various sub-
types. These insights have allowed an improved understanding over time of the of the 
major subgroups and disease entities of the amyloidoses, leading to some degree of 
improvement in diagnosis and treatment outcomes. Unfortunately, as of this writing, 
treatment outcomes still remain poor for a large fraction of patients, and there is need 
for improvement in all aspects of the evaluation and management of these diseases.
2. Early observations
Robert Kyle, of the Mayo Clinic, a leading investigator in the field of amyloidosis 
over much of the past century, meticulously detailed early observations regarding 
cases suggestive of amyloid diseases documented in the medical literature, in a his-
torical review that he published shortly after the turn of this century [1]. Kyle refer-
ences reports by Theophili Bonetti, in Bonetti’s work Sepulchretum sive Anatomia 
Practica, which is included in E. R. Long’s book A History of Pathology [2]. Bonetti’s 
reports includes descriptions of two autopsies with findings suggestive of amyloi-
dosis. The earliest of these reports is that of Nicklaus Fontanus, from the year 1639, 
whose report was of an autopsy of a young man who had evidence of epistaxis, 
jaundice, and ascities, with gross pathology showing abnormalities of the liver and 
spleen. Kyle also cites the book by Schwartz [3] to note an autopsy report from the 
year 1818, by an investigator named Merat, who described “lardaceous” changes 
in the liver - that is, changes in the appearance of the liver that appeared to show 
infiltration of the liver by a substance resembling lard - porcine fat. Subsequently, 
George Budd, in 1852, described several patients with liver infiltration by an abnor-
mal substance, and in his chemical analysis, using the techniques available at the 
time, he reported these contained a significant amount of albumin - that is, protein, 
measured at sixteen percent of the infiltrate, with only approximately six percent 
fat, despite its appearance. Two of the subjects in his series showed similar infiltra-
tion of the kidneys, a pattern consistent with current presentations of amyloidosis 
[4]. In 1814, Colin and Gaultier de Chaubry observed the blue color change seen 
when starch is stained using iodine together with sulfuric acid. The pathologist 
Rudolph Virchow applied the term “amyloid” in the year 1854 to characterize the 
brain structures corpora amylacea due to the color changes seen with the application 
of iodine, expressing the belief that there was a starch like substance present [5]. In 
1842, Carl Rokitansky reported hepatomegaly with hepatic infiltration by a gelati-
nous material, in a series of autopsies of patients with tuberculosis or syphilis. This 
may have been the first report of AA amyloidosis in the setting of chronic inflam-
mation and infection. Similarly, in the year 1867, H. Weber reported amyloidosis in 
a patient with myeloma, with amyloid having been identified in the heart, kidneys, 
and spleen, consistent with what is now termed AL amyloidosis [6].
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In the late nineteenth century, dyes were being widely explored for use in a 
variety of biochemical investigations, including for use as histopathologic stains. 
The aniline dye Congo Red was developed in 1883, when Paul Böttinger, at the Bayer 
Company in Germany, synthesized the compound as a potential pH indicator [7]. In 
1923, Bennhold reported administration of Congo Red by intravenous injection into 
humans [8]. He injected solutions of Congo Red into twenty-one healthy subjects, 
and into twenty-one patients with a variety of illnesses, including patients with 
amyloidosis. He noted that in patients with amyloidosis, Congo Red cleared from 
the blood significant faster than in healthy individuals or patients with other disease 
states. In that report, one patient with a diagnosis of amyloidosis died within a day 
of the injection of Congo Red; at autopsy, the liver and spleen appeared to have 
been stained red by the injected dye Congo Red. In addition, light microscopy of 
histopathologic slides demonstrated red staining. The observation that a so-called 
“apple-green birefringence” could be observed in tissue involved by amyloid 
deposition under polarized light microscopy was made in the mid-twentieth 
century, variously attributed to Missmahl, a student of Bennhold, and to Divry and 
Florkin [9]. Over the course of the twentieth century, the technique of Congo Red 
staining has been refined, and the chemical basis of the staining has been generally 
well characterized. In an excellent review, Yakupova and colleagues detail both 
the empiric data, as well as biochemical models, regarding Congo Red staining of 
amyloid, in the context of the knowledge of amyloid structure [10]. They detail 
the pitfalls involved in the use of Congo Red staining as a histopathologic test for 
amyloidosis, and summarize the literature, including a discussion of false positives 
and false negatives with regard to the accurate diagnosis of amyloidosis.
As X-ray diffraction became available as a technique to study submicroscopic 
structure, this technology was applied to the study of amyloid. Eanes and Glenner 
reported X-ray diffraction studies on amyloid filaments in the year 1968 [11], from 
which it appeared that amyloid is composed of polypeptide chains in a “cross β 
conformation”. Less than a decade prior to that, Cohen and Calkins applied electron 
microscopy imaging to recognize that all subtypes of amyloid exhibit a non-branch-
ing fibrillary structure [12]. Bonar and colleagues refined the characterization of 
amyloid fibrils using X-ray diffraction to show that for amyloid fibrils, the cross β 
proteins - polypeptide chains that form β pleated sheets - the individual strands of 
each β sheet run perpendicular to the fibril axis, with 4.1 Å spacing [13]. Thus, by 
the 1960s, the general structure of amyloid had been defined, although the under-
lying pathophysiology of the various subtypes remained to be more completely 
elucidated.
In recent decades, the application of high performance liquid chromatography 
(HPLC) and mass spectroscopy (MS) to the analysis of amyloid specimens has 
greatly enhanced the ability to diagnosis patients as having specific subtypes of 
amyloidosis, and thus has allowed marked improvements in disease-directed 
treatments. Mass spectroscopy is an analytical technique that is used to measure 
the mass-to-charge ratio of ions. The results are typically presented as a mass 
spectrum, a plot of intensity as a function of the mass-to-charge ratio. Comparison 
of the results of analysis of a specimen to know materials assists in identification 
of the composition of the specimen. The scientific basis for the technology of 
mass spectroscopy began with the work of Eugene Goldstein and Wilhelm Wein in 
Germany at the end of the 19th century. It was developed into a practical tool by J.J. 
Thompson in England, and refined by Arthur Jeffrey Dempster and F.W. Aston in 
the early 20th century. Similarly, HPLC a technique in analytical chemistry used 
to separate, identify, and quantify each component in a sample that is presumed 
to be a mixture. The device pumps a highly pressurized liquid solvent containing 
the sample mixture through a column filled with a solid adsorbent material, and 
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the components are thereby separated and may be identified by comparisons to 
know controls. Although conventional liquid chromatography is a technique that 
was developed much earlier, modern high pressure liquid chromatography matured 
in the 1960s and 1970s. Thus, the application of this technology to characterize 
amyloid deposits only began in the 1970s, as discussed later, regarding the work of 
Mark Pepys and colleagues in characterizing the amyloid P protein.
3. Insights into patho-biological subtypes and diagnosis
3.1 AA amyloidosis
As noted above, autopsy studies in the nineteenth century, as exemplified by 
the report by Rokitansky in 1842, mentioned above, established a relationship 
between chronic inflammatory diseases - such as tuberculosis and syphillis, and the 
development, in some of these cases, of amyloidosis. Earl P. Benditt, a pioneer in 
the field of amyloidosis, together with his colleague Nils Eriksen at the University 
of Washington, isolated, by gel electrophoresis, a protein that he initially named 
“amyloid of unknown origin” in the year 1961 [14], obtained from specimens of 
patients with “secondary” amyloidosis - that is, in patients with underlying chronic 
inflammatory diseases. A decade later, in 1971, Benditt and colleagues refined their 
identification of the amino acid structure of secondary amyloid, showing a specific 
sequence of amino acids at the N-terminus [15]. The following year, in 1972, Levin 
and colleagues reported the complete seventy-six amino acid protein sequence of an 
amyloid protein from a subject with secondary amyloidosis [16]. A number of other 
laboratories identified similar peptide sequences from specimens of secondary amy-
loidisis, differing slightly in length, but all sharing the same N-terminal sequence, 
and with lengths on the order of approximately seventy-six amino acids.
These then became known as AA amyloid, or amyloid A protein. In 1975, Linke 
and colleagues, using antibodies raised against amyloid A proteins, identified a 
serum substance that bound these antibodies. Ultimately, this 104 amino acid 
peptide was identified as the serum precursor to tissue amyloid A, and was named 
serum amyloid A, or, SAA. There is now a large body of literature detailing the 
biology of SAA; the SAA proteins are acute phase reactants, which are important 
both in lipid transport and in inflammation, and participate in the interactions 
between lipids and the inflammatory process. These molecules are also termed 
apolipoproteins, in view of the function that they fulfill in transporting lipids 
throughout the body. The genes for human serum amyloid A1 (SAA1) and human 
serum amyloid A2 protein (SAA2) map to the region of chromosome 11 p15.1, and 
are rapidly synthesized by hepatocytes and secreted into the blood in response to a 
variety of inflammatory stimuli. In experimental conditions, exposure to lipopoly-
saccharide from streptococcus pneumonia provokes a dramatic rise in SAA levels and 
is associated with chemotaxis of leukocytes as well as a cascade of other inflam-
matory responses. SAA3 appears to be a pseudo-gene, with no significant protein 
expression, and SAA4 is expressed constitutively in the liver. AA amyloid fibrils 
include deposition of SAA1 and. SAA2, and this typically occurs when a significant 
inflammatory process persists over a long period of time. An excellent recent review 
of the literature on the structure and biology of serum amyloid A was published by 
George Sach in the journal Molecular Medicine [17].
In parallel with studies that defined the identity and structure of the amyloid A 
proteins, during the 1960s a number of investigators identified a separate protein 
extracted from amyloid deposits, by exploiting antigenic properties, using antibod-
ies to isolate and characterize this protein. Prominent among these investigators 
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were Cathcart and Cohen, and their colleagues at Harvard Medical School [18]. In 
a series of experiments reported over several years, this protein was defined, and 
named amyloid P protein [19], also called in the literature amyloid P component. 
In the early 1970s, Mark Pepys in London developed a rabbit antibody to C reactive 
protein (CRP) that also precipitated second protein from serum; this proved to 
be serum amyloid P (SAP). Over the next two decades, it was discerned that both 
CRP and SAP are members of the same class, pentameric molecules that have been 
named pentraxins [20]. Pepys and colleagues reported the three dimensional struc-
ture of human SAP using X-ray crystallography in 1994, ultimately finding that this 
forms a flattened β “jelly roll” structure [21]. The gene for SAP in humans resides 
on chromosome 1 at locus 1q23.2. Human SAP avidly binds to chromatin, displac-
ing H1 histones; this has suggested that SAP may play a role in modulating DNA 
biology [22]; however much remains to be determined in this regard. An evolv-
ing literature indicates that the so-called “short pentraxins”, which include CRP 
and SAP, are participants in the innate immune response. There is data that both 
CRP and SAP interact with pathogens to activate leukocytes, as well as to regulate 
complement; this has been carefully reviewed in a paper by Cox, Pilling, and Gomer 
of the University of Texas [23]. On average, approximately fourteen percent of the 
mass of amyloid deposits are amyloid P protein, across amyloid subtypes. In 1979, 
Pepys and colleagues demonstrated that, in vitro, amyloid P protein binds to both 
primary amyloid (immunoglobulin light chain amyloid), or AL amyloid, as noted 
above, as well as binding to secondary amyloid, such as AA amyloid. The amyloid 
P component is thought to stabilize other fibrillary molecules within the amyloid, 
such as the amyloid A protein, and inhibit fibril breakdown. Analysis of amyloid 
deposits by high performance liquid chromatography and mass spectroscopy has 
become an important tool in confirming the specific subtype of amyloidosis in a 
patient; a biopsy specimen processed by laser micro dissection can generally be sent 
to a reference laboratory for such analysis [24]. Such analysis permits determination 
and confirmation of the specific subtype of amyoidosis; e.g., that a particular speci-
men contains AA amyloid, AL amyloid, ATTR amyloid, or a less common subtype 
among the amyloidoses. This mass spectroscopy and high performance chromatog-
raphy analysis has demonstrated the presence of other moieties present in amyloid 
deposits, prominently including glycos-aminoglycans, in addition to the ubiquitous 
amyloid P protein.
In the late 1980s, Pepys and colleagues developed the diagnostic technique of 
radioactive iodine labeled SAP scintigraphy for diagnosis and evaluation of patients 
with various forms of amyloidosis [25]. This diagnostic modality remains an impor-
tant tool to this day in the assessment of patients with suspected to documented 
amyloidosis, including for the purpose of monitoring response to therapy.
In 2007, researchers in the United Kingdom published the findings of a lon-
gitudinal study of 374 patients with AA amyloidosis followed at the Royal Free 
hospital [26]. They reported that median survival from diagnosis was 133 months, 
and kidney dysfunction was the predominant clinical manifestation. They further 
reported that mortality and renal impairment correlated positively with SAA 
serum concentrations. In this series, underlying chronic inflammatory disor-
ders included chronic inflammatory arthritis most commonly - predominantly 
Rheumatoid arthritis, chronic infections including bronchiectasis, infections in the 
setting of chronic injection drug abuse, and infectious complications of paraple-
gia. Less common underlying inflammatory processes included osteomyelitis, 
tuberculosis, and periodic fever syndromes such as familial Mediterranean fever; 
Crohn’s disease, and Castleman’s disease. Successful management of the underly-
ing inflammatory disorder was associated with improved outcome and lower levels 
of SAA in the blood.
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3.2 AL amyloidosis
Robert Kyle of the Mayo Clinic has published several historical reviews of the 
disease multiple myeloma. In a manuscript detailing medical observations and 
insights regarding myeloma, Kyle and Rajkumar [27] cite a case reported in the 
year 1844, of a 39 year old woman who experienced fatigue and bone pain associ-
ated with multiple fractures [28]. The patient died approximately four years after 
her initial presentation, and autopsy findings included marrow replacement by 
aberrant cells. A landmark case was that of the patient Thomas McBean, who 
also developed fatigue and bone pain. Urine specimens from Mr. McBean were 
brought to Henry Bence Jones, a chemical pathologist, after the patient’s attending 
physician noted a high specific gravity to the urine, as well as opacity of the urine 
when boiled. Bence Jones reported the findings of proteinuria [29, 30], although 
he considered that the protein was an oxidized albumin. Waldeyer was the first to 
use the term plasma cell to describe a specific cell type [31]; however, it was Wright 
who felt that the malignant cells of myeloma were plasma cells [32]. H. Weber, in 
1867, reported an autopsy with findings of non-traumatic fractures of the sternum, 
with the marrow replaced by an infiltrate of small uncleared cells. The heart was 
hypertrophied, and amyloid was identified in both the kidneys and the spleen - a 
presentation consistent with myeloma complicated by amyloidosis [33]. Kyle writes 
that this was the first report of amyloidosis associated with multiple myeloma. 
During the first half of the twentieth century, technology evolved to permit the 
identification of different classes of Bence Jones proteins, and in 1962, Edelman and 
Gally showed that serum monoclonal light chains from a patient with IgG myeloma 
shared the same amino acid sequence as the patient’s Bence Jones protein, establish-
ing that Bence Jones protein is derived from clonal paraprotein [34].
Magnus-Levy, who began his career in Germany, but relocated to the United 
States early during the Second World War, documented his conjecture that Bence 
Jones protein excreted in the urine of myeloma patients might be “the mother 
substance” of amyloidosis; this was published in the year 1931 [35]. In 1946, 
Herbut and Erf showed that amyloid could be identified within plasma cells, and 
concluded corrrectly that plasma cells were the source of amyloid in the setting of 
myeloma [36]. Thus, by the mid-twentieth century, it was evident that one form 
of amyloidosis was the consequence of a clonal plasma cell disorder. Glenner and 
colleagues demonstrated in vitro that monoclonal immunoglobulin light chains 
from myeloma patients could form amyloid fibrils under experimental conditions, 
which precipitated after pepsin exposure; the precipitates stained with Congo Red, 
and demonstrated green birefringence by polarizing microscopy [37]. In the past 
several decades, it has been shown that specific clonal light chain sequences result 
in a significant predisposition to misfold, and therefore deposit as amyloid; among 
these, the light chain variable region sequences Vλ1, Vλ2, Vλ3, Vλ6, and Vκ1 are 
particularly over-represented as amyloid protein, as compared to other immuno-
globulin variable region sequences [38].
The treatment of primary, or, AL amyloidosis remains unsatisfactory. This 
is, in part, due to a frequent delay in diagnosis, which may result either from the 
lack of specificity in early symptoms, or due to presentation when there is already 
significant end-organ damage that precludes aggressive therapy [39]. Treatment of 
all subtypes of amyloidosis are directed, at least in part, to suppressing production 
of the misfolding protein. In AL amyloidosis, this means suppressing production 
of clonal light chains secreted by the clonal plasma cells. In 1958, Blokhin and 
colleagues reported benefit from treatment using melphalan in a small cohort of 
patients [40]. Similarly, in 1962, Maas reported a study in myeloma patients treated 
using prednisone, versus placebo, and documented the at least transient objective 
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anti-neoplastic activity of corticosteroid therapy in treating myeloma [41]. In 1969, 
Alexanian and colleagues published a seminal prospective, randomized clinical trial 
that established the combination of melphalan and prednisone as the standard of 
care as systemic anti-neoplastic therapy for multiple myeloma [42]. That standard 
prevailed for several decades, until the turn of this century, when novel agents, 
including the imids and subsequently the proteosome inhibitors, were developed. 
Consequently, in view of the ability of theses drugs to suppress the malignant clone 
of plasma cells in overt myeloma, the same drugs were employed to suppress the 
clonal plasma cell population producing amyloid in AL amyloidosis. Toward the 
end of the twentieth century, colchicine was used as therapy for AL amyloidosis. 
However, a prospective, randomized clinical trial comparing colchicine to melpha-
lan plus prednisone, or all three drugs together, in patients with AL amyloidosis, 
showed a survival advantage from melphalan and prednisone [43]. This was 
therefore conventional therapy for AL amyloidosis for several decades, until the 
advent of the newer agents used to treat multiple myeloma - the imids and proteo-
some inhibitors, and the demonstration that a favorable outcome - as compared 
to historical controls - could be obtained in carefully selected patients treated 
using high dose melphalan with autologous hematopoietic rescue. To date, there 
have been no large, prospective randomized clinical trials in AL amyloidosis of the 
newer agents, nor of autologous transplants in AL amyloidosis. However, based on 
numerous Phase II trials, a general consensus has evolved, with patients deemed 
fit taken to autologous transplant, often after induction therapy. One example of 
such a consensus approach is an algorithm for treatment published by the Swiss 
Amyloidosis Network [44]. This group currently recommends induction therapy 
using the combination of cyclophosphamide, bortezomib, and dexamethasone 
(“CyBorD”) followed by high dose melphalan with autologous hematopoietic 
rescue, for transplant-eligible patients. For transplant ineligible patients, this group 
recommends the monoclonal antibody daratumumab, directed against the plasma 
cell surface protein CD 38, either alone or with combination with other agents. 
Current investigational therapeutic approaches include novel experimental treat-
ments, such as a monoclonal antibody that can bind and potentially extract amyloid 
P protein from organ deposits [45].
3.3 ATTR amyloidosis
In 1952, a neurologist, Andrade, reported detailed observations regarding a 
cluster of patients with neurological deficits in the Oporto region of Portugal, with 
some of those observations dating back to 1939 [46]. The afflicted patients shared 
clinical features of peripheral motor weakness and peripheral sensory deficits, as 
well as, in many cases, gastrointestinal and sexual dysfunction. Histopathologic 
examination revealed amyloid deposition, and a familial, autosomal dominant 
pattern of inheritance was noted. Similar observations were made of familial amy-
loidosis with primarily neurological manifestations - most prominently peripheral 
neuropathy and autonomic neuropathy - in Japan, and in Scandinavia in the latter 
part of the twentieth century. Eventually, hereditary amyloidosis was identified in 
many populations, with clinical syndromes that presented primarily as neurologi-
cal dysfunction, or with clinical syndromes that presented primarily with cardiac 
disease. Abnormal electrophoretic mobility transthyretin was noted in many of 
these cases. With the advent of the technologies of molecular biology of the gene, 
the vast majority of hereditary amyloidosis cases were found to be due to a variety 
of mutations in the protein transthyretin became recognized. Hereditary trans-
thyretin amyloidosis, also termed ATTRv amyloidosis (“ATTR variant”) is generally 
an autosomal dominantly inherited disorder, due to a variety of mutations in the 
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TTR gene that encodes for transthyretin. The TTR gene product is a homodimeric 
plasma protein produced primarily in the liver, with additional production and 
secretion by the choroid plexus and by retinal epithelia. The TTR protein serves 
both as a thyroid hormone binding protein, as well as a retinol binding protein, 
and was originally called “pre-albumin” due to its migratory pattern on protein 
gel electrophoresis, running ahead of the albumin peak [47]. Beginning in the late 
1980s into the early 1990s, DNA sequencing of the TTR gene by many investigators 
uncovered numerous mutations in TTR associated with amyloidosis, manifesting 
as predominantly either neurological disease, or as cardiac disease- typically with 
arrhythmia, with or without heart failure syndrome [48]. As of this writing, more 
than 125 different TTR mutations have been identified in the TTR gene locus, that 
are associated with ATTR amyloidosis. The most common TTR variants in the 
United States include (1) the Val30Met mutation, which is the most commonly 
identified mutation worldwide. The syndrome Familial amyloid polyneuropathy 
(termed FAP) is most commonly caused by Val30Met. Other relatively common 
driver mutations include (2) the Thr60Ala mutation, (3) the Leu58His mutation, 
(4) the Ser77Tyr mutation, and (5) the Val122Ile mutation. This last mutation is 
predominantly seen in the African-American population, and typically presents 
as cardiomyopathy. The syndrome Familial Amyloid Cardiomyopathy (FAC) is 
commonly caused by Val122lle.
During the same time period, it was recognized, primarily from autopsy studies, 
that there were individuals who were found to have evidence of systemic amyloid 
deposition at an advanced age, primarily in the heart, but in some cases affecting 
the peripheral nerves, and this has been termed Systemic Senile Amyloidosis (SSA). 
Often there is no clinical heart disease in these individuals, but some of these indi-
viduals will indeed develop cardiac disease, ranging from arrhythmia to heart fail-
ure syndrome. There is also increasing evidence that ATTRwt disease is a cause of 
carpel tunnel syndrome in the elderly. Analysis of the amyloid from these patients 
showed transthyretin as the major component of the amyloid, together with serum 
amyloid A protein; there is also data to suggest that the molecule Clusterin may play 
a role in the formation of this form of amyloid [49]. Clusterin, also called apolipo-
protein J, is a heterodimeric protein member of the heat shock protein family, and 
participates in apoptosis. Critically, gene sequencing of the TTR in these individuals 
is normal, as was first documented in a study by Westermark and colleagues in 1990 
[50]. This subtype of ATTR amyloidosis is also termed ATTRwt, that is, wild-type 
ATTR Amyloidosis. In this disorder, there is misfolding of transthyretin, despite the 
normal gene sequence.
When ATTR amyloidosis is suspected due to clinical findings, a tissue diagnosis 
of amyloid deposition is a definitive procedure. The finding of amyloid deposition, 
however, should be followed by biochemical analysis of the amyloid, either by 
mass spectroscopy and high performance chromatography, or by sequencing of the 
TTR gene, or both. As noted above, ATTRwt is defined in part by a normal gene 
sequence of TTR. As discussed previously, as in all subtypes of systemic amyloido-
sis, nuclear medicine studies may be diagnostic [25, op cit]. Myocardial radiotracer 
uptake at bone scintigraphy using an agent such as technicium-99 pyrophosphate is 
both sensitive and specific for a diagnosis of cardiac amyloid due to ATTR amyloid, 
once monoclonal light chain amyloid has been excluded by immunological studies. 
In the management of ATTRv amyloidosis, liver transplant became a standard of 
care over the past 25 years, as this replaces the source of the variant, or, mutated 
TTR with a liver that produces normal TTR. Liver transplant has been documented 
to improve overall survival in ATTRv amylodosis [51]. In ATTRv amyloidosis, the 
mutations in the TTR gene appear to destabilize the normal tetrameric state of the 
transthyretin protein, resulting in dissociation into monomers prone to misfolding 
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and aggregating. Consequently, it was hypothesized that agents that could stabilize 
the TTR tetramers might ameliorate the disease by reducing amyloid fibril forma-
tion and deposition. Tafamidis is an oral agent, currently approved in Europe for 
the treatment of early stage polyneuropathy ATTR amyloidosis, which appears to 
work by stabilizing the transthyretin tetramer. In prospective, randomized clinical 
trials, Tafamidis was shown to be safe, with evidence of that it retards neurologi-
cal deterioration [52, 53]; however efficacy was questionable for patients with 
advanced disease. Subsequently, a prospective, randomized, placebo controlled trial 
of Tafamidis in ATTR cardiomyopathy, both variant and wild type, NCT01994889, 
showed a thirty percent reduction in mortality as compared to placebo [54]. This 
led to FDA approval in the United States of Tafamidis for the treatment of ATTR 
cardiomyopathy. In a randomized, placebo controlled clinical trial, the non-
steroidal anti-inflammatory agent diflunisal was compared to placebo, diflunisal 
reduced progression of neuropathy significantly in patients with hereditary ATTR 
amyloidosis [55]. However, there were significant toxicities associated with use 
of diflunisal, including renal injury, in this study. Use of diflunisal is “off-label”, 
but is certainly used at this time for management of some patients with ATTRv 
amyloidosis.
More recently, two parenteral agents have been introduced for the treatment 
of ATTR amyloidosis with polyneuropathy, both of which work by reducing 
messenger RNA for TTR, and thus reducing production of the amyloidogenic 
TTR protein. Inotersen, an anti-sense oligonucleotide that binds up TTR mRNA, 
is administered subcutaneously once weekly, and was approved on the basis of 
the results of a pivotal randomized clinical trial. In that study, the Neuro-TTR 
trial, patients randomized to Inotersen demonstrated sustained reductions in 
transthyretin protein production, and statistically significant improvement in 
quality of life [56]. Similarly, Patisiran is a small, interfering RNA molecule given 
intravenously once every three weeks. In the Apollo study, patients with heredi-
tary ATTR polyneuropathy were randomized to receive Patisiran versus placebo. 
Results documented a clinical improvement in neuropathy at eighteen months for 
patients treated using Patisiran versus placebo [57]. Both Inotersen and Patisiran 
are currently approved for treatment of ATTR polyneuropathy. In sum, for the 
estimated 50,000 people living with hereditary ATTR amyloidosis, there are 
now a number of medical treatment options with less mortality risk than liver 
transplant.
4. Other hereditary amyloidosis
Since 1990, several other molecules with mutations that predispose to 
misfolding have been discovered as rare causes of amyloidosis. These include 
hereditary renal amyloidosis due to mutations in lysozyme [58] giving rise to ALys 
Amyloidosis; mutations in fibrinogen, giving rise to AFib amyloidosis [59] apolipo-
proteins AI, giving rise to AApoAI amyloidosis; mutations in Apolipoprotein AII, 
giving rise to AApoAII amyloidosis [60]; mutations in the protein gelsolin, giving 
rise to AGel amyloidosis [61].
In addition, leukocyte chemotactic factor-2 related amyloidosis is an unusual 
amyloid disorder associated primarily with chronic kidney disease. Originally 
characterized in 1998, human LECT2 is a protein that is predominantly synthe-
sized by hepatocytes. As well as having neutrophil chemotactic properties, it also 
appears to participate in repair of tissue injury. Since the beginning of the 21st 
century, an increasing number of cases of patients with localized renal amyloidosis 
associated with chronic kidney disease have been found, on chemical analysis, to 
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have amyloid comprised largely of LECT2. There is a marked over-representation 
of Hispanic patients with LECT2 amyloidosis, in particular patients with back-
grounds from Mexico. Although the majority of these unusual cases have renal 
involvement only, investigators at the University of California reported a case 
with both renal and pulmonary involvement [62]. Genetic polymorphisms in the 
LECT2 gene have been identified that appear to predispose to the development of 
amyloidosis, and the over-representation of Hispanic patients suggests that there 
is a genetic component to this disease process. However, the precise etiology of the 
over-expression and deposition of LECT2 has not been fully established as of this 
writing.
5. Dialysis associated amyloidosis
Dialysis-related amyloidosis (“DRA”) is a relatively common complication 
of chronic renal dialysis therapy, with the deposition of amyloid fibrils that are 
composed primarily of the molecule β2 microglobulin (“β2M”). β2M is typi-
cally hydrogen bonded to the MHC class I structure present on nucleated cell 
surfaces, but urea in the blood can break that bond, with β2M then circulating 
in the plasma. In 1975, carpel tunnel syndrome was recognized as a complication 
of long term hemodialysis [63]. Within a decade, this was found to be associ-
ated with histology findings of amyloid [64], and β2M was found to accumulate 
in patients maintained on dialysis. Soon thereafter, the amyloid deposits seen 
in this setting were documented to be composed in large part of β2M [65]. The 
amyloid in the setting of chronic renal dialysis therapy is deposited in osteo-
porosis-articular structures and in visceral organs, particularly at the wrists, 
the sternum, the knees, and the kidneys. Bone cysts also occur. Under normal 
physiological conditions, β2M is eliminated through glomerular filtration and 
subsequent reabsorption and catabolism by the proximal tubules. In general, the 
serum level of β2M is inversely related to the glomerular filtration rate; there-
fore, in end-stage renal disease patients, β2M levels may increase up to 60-fold. 
The β2M may then mis-fold, polymerize, and become deposited in the tissues; 
mis-folded intermediate forms of β2M have been reported [66], particularly 
truncated forms of β2M that lack the six N-terminal amino acids [67]. It is diffi-
cult to determine the true prevalence of DRA, because formal evaluation is often 
not undertaken. DRA is relatively common in patients maintained on long-term 
hemodialysis, typically for at least several years, but it has also been documented 
in patients undergoing continuous ambulatory Peritoneal dialysis. Aggressive 
dialysis, to reduce the chronic elevation of β2M is a costly, but effective, manage-
ment approach.
Instances of localized deposition of amyloid – as distinct from systemic amy-
loidosis – were clearly recognized as a distinct clinical entity only in the twentieth 
century. Among the earliest reports of localized amyloid deposition is that by 
Gellerstedt in the year 1938 [68]. He described Congo Red positive amyloid deposits 
in the islets of langerhans within the pancreas, in a diabetic patient. Since that time, 
localized amyloidosis has been reported to occur, in rare cases, in nearly every organ 
in humans. However, the most commonly reported sites, by far, are the skin and 
the upper aero-digestive tract. Weidner and colleagues from Germany reviewed 
the literature regarding localized cutaneous amyloidosis, and identified small case 
series and case reports dating back to the year 1985 [69]. Similarly, the upper aero-
digestive tract is a relatively frequent site for identification of localized amyloid 
deposits, in the absence of systemic disease. However, these cases are still fairly rare 
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overall, in general, and information regarding localized amyloidosis of the upper 
aero-digestive tract is primarily derived from case reports and small series [70]. It is 
possible that the medical literature may be skewed, and upper aero-digestive tract 
amyloid deposits may be over-represented, due to the fact that mass lesions in the 
upper aero-digestive tract give rise to symptoms even when the lesions are quite 
small, but there are a relatively large number of case reports of localized amyloid in 
the regions from the oropharynx to the pulmonary carina. In a retrospective review 
from Germany, the larynx was the most commonly involved site, although in that 
series localized disease was also seen in the tongue, trachea, and pharynx [71]. 
Similarly, there are many reports of localized amyloid in the lower gastrointestinal 
tract, likely due in part to incidental discovery during screening colonoscopy for 
colon cancer. An early autopsy series reported by Ravid and colleagues, published in 
the year 1967, detailed the findings from 391 necropsies performed at Tel HaShomer 
Hospital [68, op cit]. Most cases of localized amyloidosis are found to be AL amy-
loid, but AA amyloid may also be seen. It remains unclear why some patients with 
localized AL amyloid may not progress to systemic amyloid, nor why there is a 
tropism for the amyloid deposition to the specific sites in such cases. This is a fertile 
area for additional research.
6. Cerebral vascular amyloidosis
Cerebral amyloid angiopathy is a disorder in which there is accumulation of 
amyloid within the walls capillaries, as well as of small and medium sized arterial 
vessels within the nervous system. This results in weakening of the vessels over 
time, and the disorder typically presents in the elderly. Clinically, it may manifest as 
either micro-hemorrhages, which can result in cognitive impairment and possibly 
vascular dementia, or may manifest as intra-cerebral hemorrhage, which may be 
catastrophic. An early description of cerebral amyloid angiopathy was published by 
Ishiguro and colleagues in the year 1984. In this autopsy series, the authors identi-
fied seven cases in which patients presented with either intra-cerebral hemorrhage 
or with dementia. At autopsy, amyloid deposition was observed in the smaller arte-
rial vessels, including at the sites of hemorrhage [72]. Later analysis of the amyloid 
showed this to be deposition of Amyloid Precursor Protein (APP), a membrane 
protein that is present in high concentrations at neuronal synapses. Proteolysis of 
APP results in amyloid Aβ polypeptides. These are a principle component of the 
amyloid found in cerebral vascular amyloidosis; amyloid Aβ polypeptide is also a 
component of the amyloid deposits in Alzheimer’s Disease. However, in Alzheimer’s 
Disease, the Aβ fragments typically extend to amino acids position 42, whereas in 
cerebral vascular amyloidosis, the Aβ fragments extend only to amino acid positions 
39 or 40 [73]. Neurofibrillary tangles, a hallmark of Alzheimer’s Disease, are not 
seen in cerebral vascular amyloidosis.
7. Amyloid in Alzheimer’s disease
Amyloid deposition is an integral aspect of the histopathology of Alzheimer’s 
Disease. However, the amyloid is only one aspect of the dramatic microscopic 
changes seen in the brain when affected by Alzheimer’s disease. Alzheimer’s disease 
is discussed in detail in other chapters of this volume, and therefore will not be 
reviewed here. A timeline of the many of the most significant observations and 
developments in the amyloidoses is provided in Figure 1.
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